Intellia stock price target maintained at $30 by Citizens on HAE data

Citizens maintained a $30 price target on Intellia Therapeutics (NASDAQ:NTLA) shares, following data updates on its lonvo-z treatment for hereditary angioedema. The firm reported that 100% of patients were free from long-term prophylaxis and two-thirds attack-free during the ACAAI presentation. Intellia showcased additional duration data and garnered significant patient demand for the therapy, supported by key opinion leaders.

The company's sum-of-the-parts analysis values the HAE opportunity at $20 per share, while Intellia's shares currently trade at $10.55 with a market cap of $1.48 billion. InvestingPro analysis suggests the biotech is undervalued, with more cash than debt on its balance sheet and a robust current ratio of 6.31. However, the company is rapidly depleting cash, which is common for development-stage therapeutics firms.

The one-and-done lonvo-z treatment offers attack reductions without continuous therapy. Recent financing around lonvo-z strengthens the HAE opportunity. Intellia Therapeutics is scheduled to report earnings on November 6, leading to options data hinting at a potential 3.8% stock movement. The FDA has accepted lonvo-z's Biologics License Application, granted priority review, and set a Prescription Drug User Fee Act target action date of March 10, 2027.

This could make lonvo-z the first in vivo CRISPR-based therapy for hereditary angioedema, positioning Intellia Therapeutics favorably in the biotech landscape.